Association of RSV-related hospitalization and non-compliance with palivizumab among commercially insured infants: a retrospective claims analysis
Palivizumab has been shown to decrease the incidence of hospitalization due to respiratory syncytial virus (RSV) in infants at risk of severe RSV disease. We examined the association between compliance with palivizumab dosing throughout the RSV season and risk of RSV-related hospitalization in clini...
Gespeichert in:
| Veröffentlicht in: | BMC infectious diseases 2013-07, Vol.13 (1), p.334-334, Article 334 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 334 |
|---|---|
| container_issue | 1 |
| container_start_page | 334 |
| container_title | BMC infectious diseases |
| container_volume | 13 |
| creator | Stewart, Dan L Ryan, Kellie J Seare, Jerry G Pinsky, Brett Becker, Laura Frogel, Michael |
| description | Palivizumab has been shown to decrease the incidence of hospitalization due to respiratory syncytial virus (RSV) in infants at risk of severe RSV disease. We examined the association between compliance with palivizumab dosing throughout the RSV season and risk of RSV-related hospitalization in clinical practice.
Subjects who were born and discharged from the hospital before the RSV season and received ≥1 palivizumab dose during their first RSV season were identified from a large US commercial health insurance database between 01/01/03 and 12/31/09. Subjects were deemed compliant if they received ≥5 palivizumab doses without gaps (>35 days) and their first dose was received by November 30. RSV-related hospitalizations were identified using ICD-9-CM diagnosis codes and examined over 2 observation periods: post-index dose and RSV season. A Cox proportional hazard model was used to evaluate the association between non-compliance and RSV-related hospitalization.
Of the 5,003 subjects who received palivizumab, 62% were deemed non-compliant. Non-compliant subjects had significantly higher unadjusted rates of RSV-related hospitalizations compared to compliant subjects during both observation periods (post-index: 6.1 vs. 2.8 per 100 infant seasons, p |
| doi_str_mv | 10.1186/1471-2334-13-334 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3727980</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A534607578</galeid><sourcerecordid>A534607578</sourcerecordid><originalsourceid>FETCH-LOGICAL-c559t-c214ddb47809b937d5d5b6f0a7c87e34b90b09aa68768f1c206fef305e5a0d703</originalsourceid><addsrcrecordid>eNqNkktr3DAUhU1padK0-66KoKssnEqWbcldFIbQRyAQSNpsxbUszyjo4UrytJOf0V9cDZNOM9BF0eKKe79zQFenKF4TfEYIb9-RmpGyorQuCS1zeVIc71tPH92Pihcx3mFMGK-658VRRTnDmLfHxa9FjF5qSNo75Ed0fXNbBmUgqQGtfJx0AqPvd2NwA3LeldLbyWhwUqEfOq3QlJG1vp8t9Aisd0uUCatCtjVmg7SLc8h22o3gUnyPAAWVQjZXMum1QtKAtjHbg9lEHV8Wz0YwUb16qCfFt08fv55_KS-vPl-cLy5L2TRdKmVF6mHoa8Zx13eUDc3Q9O2IgUnOFK37Dve4A2g5a_lIZIXbUY0UN6oBPDBMT4oPO99p7q0apHIpgBFT0BbCRnjQ4nDi9Eos_VpQVrGObw3ePhgE_31WMYk7P4f8iihITViNWYW7v9QSjBJ5CT6bSaujFIuG1i1mDeOZOvsHlc-grJbeqVHn_oHg9ECQmaR-piXMMYqLm-v_Z69uD1m8Y2X-oRjUuF8IwWIbOrFNldimShAqcsmSN48XuRf8SRn9DUSC020</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1417407209</pqid></control><display><type>article</type><title>Association of RSV-related hospitalization and non-compliance with palivizumab among commercially insured infants: a retrospective claims analysis</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>Springer Nature - Complete Springer Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Stewart, Dan L ; Ryan, Kellie J ; Seare, Jerry G ; Pinsky, Brett ; Becker, Laura ; Frogel, Michael</creator><creatorcontrib>Stewart, Dan L ; Ryan, Kellie J ; Seare, Jerry G ; Pinsky, Brett ; Becker, Laura ; Frogel, Michael</creatorcontrib><description>Palivizumab has been shown to decrease the incidence of hospitalization due to respiratory syncytial virus (RSV) in infants at risk of severe RSV disease. We examined the association between compliance with palivizumab dosing throughout the RSV season and risk of RSV-related hospitalization in clinical practice.
Subjects who were born and discharged from the hospital before the RSV season and received ≥1 palivizumab dose during their first RSV season were identified from a large US commercial health insurance database between 01/01/03 and 12/31/09. Subjects were deemed compliant if they received ≥5 palivizumab doses without gaps (>35 days) and their first dose was received by November 30. RSV-related hospitalizations were identified using ICD-9-CM diagnosis codes and examined over 2 observation periods: post-index dose and RSV season. A Cox proportional hazard model was used to evaluate the association between non-compliance and RSV-related hospitalization.
Of the 5,003 subjects who received palivizumab, 62% were deemed non-compliant. Non-compliant subjects had significantly higher unadjusted rates of RSV-related hospitalizations compared to compliant subjects during both observation periods (post-index: 6.1 vs. 2.8 per 100 infant seasons, p < 0.001; RSV season: 5.9% vs. 2.3%; p < 0.001). In multivariate analyses, non-compliance was significantly associated with higher risk of RSV-related hospitalization (HR = 2.01; p < 0.001). Of the 225 RSV-related hospitalizations observed during the RSV season, 61 (27%) occurred before the first dose of palivizumab.
Subjects who did not receive monthly dosing of palivizumab throughout the RSV season had significantly higher rates of RSV-related hospitalizations. The RSV-related hospitalizations prior to the first dose of palivizumab suggest some dosing was started too late.</description><identifier>ISSN: 1471-2334</identifier><identifier>EISSN: 1471-2334</identifier><identifier>DOI: 10.1186/1471-2334-13-334</identifier><identifier>PMID: 23870086</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Antibodies, Monoclonal, Humanized - therapeutic use ; Antiviral Agents - therapeutic use ; Biotechnology industry ; Care and treatment ; Children & youth ; Codes ; Compliance ; Disease ; Dosage and administration ; Drug dosages ; Drug therapy ; FDA approval ; Female ; For-Profit Insurance Plans - statistics & numerical data ; Health insurance industry ; Hospitalization ; Hospitalization - statistics & numerical data ; Hospitals ; Humans ; Infant ; Infant, Newborn ; Infants ; Insurance Claim Review ; Male ; Medication Adherence ; Methods ; Multivariate analysis ; Neuromuscular diseases ; Palivizumab ; Patient compliance ; Pediatrics ; Pharmacy ; Pneumonia ; Respiratory syncytial virus infection ; Respiratory Syncytial Virus Infections - drug therapy ; Retrospective Studies ; Seasons ; Studies ; Variables</subject><ispartof>BMC infectious diseases, 2013-07, Vol.13 (1), p.334-334, Article 334</ispartof><rights>COPYRIGHT 2013 BioMed Central Ltd.</rights><rights>2013 Stewart et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2013 Stewart et al.; licensee BioMed Central Ltd. 2013 Stewart et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c559t-c214ddb47809b937d5d5b6f0a7c87e34b90b09aa68768f1c206fef305e5a0d703</citedby><cites>FETCH-LOGICAL-c559t-c214ddb47809b937d5d5b6f0a7c87e34b90b09aa68768f1c206fef305e5a0d703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3727980/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3727980/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23870086$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stewart, Dan L</creatorcontrib><creatorcontrib>Ryan, Kellie J</creatorcontrib><creatorcontrib>Seare, Jerry G</creatorcontrib><creatorcontrib>Pinsky, Brett</creatorcontrib><creatorcontrib>Becker, Laura</creatorcontrib><creatorcontrib>Frogel, Michael</creatorcontrib><title>Association of RSV-related hospitalization and non-compliance with palivizumab among commercially insured infants: a retrospective claims analysis</title><title>BMC infectious diseases</title><addtitle>BMC Infect Dis</addtitle><description>Palivizumab has been shown to decrease the incidence of hospitalization due to respiratory syncytial virus (RSV) in infants at risk of severe RSV disease. We examined the association between compliance with palivizumab dosing throughout the RSV season and risk of RSV-related hospitalization in clinical practice.
Subjects who were born and discharged from the hospital before the RSV season and received ≥1 palivizumab dose during their first RSV season were identified from a large US commercial health insurance database between 01/01/03 and 12/31/09. Subjects were deemed compliant if they received ≥5 palivizumab doses without gaps (>35 days) and their first dose was received by November 30. RSV-related hospitalizations were identified using ICD-9-CM diagnosis codes and examined over 2 observation periods: post-index dose and RSV season. A Cox proportional hazard model was used to evaluate the association between non-compliance and RSV-related hospitalization.
Of the 5,003 subjects who received palivizumab, 62% were deemed non-compliant. Non-compliant subjects had significantly higher unadjusted rates of RSV-related hospitalizations compared to compliant subjects during both observation periods (post-index: 6.1 vs. 2.8 per 100 infant seasons, p < 0.001; RSV season: 5.9% vs. 2.3%; p < 0.001). In multivariate analyses, non-compliance was significantly associated with higher risk of RSV-related hospitalization (HR = 2.01; p < 0.001). Of the 225 RSV-related hospitalizations observed during the RSV season, 61 (27%) occurred before the first dose of palivizumab.
Subjects who did not receive monthly dosing of palivizumab throughout the RSV season had significantly higher rates of RSV-related hospitalizations. The RSV-related hospitalizations prior to the first dose of palivizumab suggest some dosing was started too late.</description><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biotechnology industry</subject><subject>Care and treatment</subject><subject>Children & youth</subject><subject>Codes</subject><subject>Compliance</subject><subject>Disease</subject><subject>Dosage and administration</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>FDA approval</subject><subject>Female</subject><subject>For-Profit Insurance Plans - statistics & numerical data</subject><subject>Health insurance industry</subject><subject>Hospitalization</subject><subject>Hospitalization - statistics & numerical data</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Infants</subject><subject>Insurance Claim Review</subject><subject>Male</subject><subject>Medication Adherence</subject><subject>Methods</subject><subject>Multivariate analysis</subject><subject>Neuromuscular diseases</subject><subject>Palivizumab</subject><subject>Patient compliance</subject><subject>Pediatrics</subject><subject>Pharmacy</subject><subject>Pneumonia</subject><subject>Respiratory syncytial virus infection</subject><subject>Respiratory Syncytial Virus Infections - drug therapy</subject><subject>Retrospective Studies</subject><subject>Seasons</subject><subject>Studies</subject><subject>Variables</subject><issn>1471-2334</issn><issn>1471-2334</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNqNkktr3DAUhU1padK0-66KoKssnEqWbcldFIbQRyAQSNpsxbUszyjo4UrytJOf0V9cDZNOM9BF0eKKe79zQFenKF4TfEYIb9-RmpGyorQuCS1zeVIc71tPH92Pihcx3mFMGK-658VRRTnDmLfHxa9FjF5qSNo75Ed0fXNbBmUgqQGtfJx0AqPvd2NwA3LeldLbyWhwUqEfOq3QlJG1vp8t9Aisd0uUCatCtjVmg7SLc8h22o3gUnyPAAWVQjZXMum1QtKAtjHbg9lEHV8Wz0YwUb16qCfFt08fv55_KS-vPl-cLy5L2TRdKmVF6mHoa8Zx13eUDc3Q9O2IgUnOFK37Dve4A2g5a_lIZIXbUY0UN6oBPDBMT4oPO99p7q0apHIpgBFT0BbCRnjQ4nDi9Eos_VpQVrGObw3ePhgE_31WMYk7P4f8iihITViNWYW7v9QSjBJ5CT6bSaujFIuG1i1mDeOZOvsHlc-grJbeqVHn_oHg9ECQmaR-piXMMYqLm-v_Z69uD1m8Y2X-oRjUuF8IwWIbOrFNldimShAqcsmSN48XuRf8SRn9DUSC020</recordid><startdate>20130719</startdate><enddate>20130719</enddate><creator>Stewart, Dan L</creator><creator>Ryan, Kellie J</creator><creator>Seare, Jerry G</creator><creator>Pinsky, Brett</creator><creator>Becker, Laura</creator><creator>Frogel, Michael</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QL</scope><scope>7T2</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope></search><sort><creationdate>20130719</creationdate><title>Association of RSV-related hospitalization and non-compliance with palivizumab among commercially insured infants: a retrospective claims analysis</title><author>Stewart, Dan L ; Ryan, Kellie J ; Seare, Jerry G ; Pinsky, Brett ; Becker, Laura ; Frogel, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c559t-c214ddb47809b937d5d5b6f0a7c87e34b90b09aa68768f1c206fef305e5a0d703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biotechnology industry</topic><topic>Care and treatment</topic><topic>Children & youth</topic><topic>Codes</topic><topic>Compliance</topic><topic>Disease</topic><topic>Dosage and administration</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>FDA approval</topic><topic>Female</topic><topic>For-Profit Insurance Plans - statistics & numerical data</topic><topic>Health insurance industry</topic><topic>Hospitalization</topic><topic>Hospitalization - statistics & numerical data</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Infants</topic><topic>Insurance Claim Review</topic><topic>Male</topic><topic>Medication Adherence</topic><topic>Methods</topic><topic>Multivariate analysis</topic><topic>Neuromuscular diseases</topic><topic>Palivizumab</topic><topic>Patient compliance</topic><topic>Pediatrics</topic><topic>Pharmacy</topic><topic>Pneumonia</topic><topic>Respiratory syncytial virus infection</topic><topic>Respiratory Syncytial Virus Infections - drug therapy</topic><topic>Retrospective Studies</topic><topic>Seasons</topic><topic>Studies</topic><topic>Variables</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stewart, Dan L</creatorcontrib><creatorcontrib>Ryan, Kellie J</creatorcontrib><creatorcontrib>Seare, Jerry G</creatorcontrib><creatorcontrib>Pinsky, Brett</creatorcontrib><creatorcontrib>Becker, Laura</creatorcontrib><creatorcontrib>Frogel, Michael</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMC infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stewart, Dan L</au><au>Ryan, Kellie J</au><au>Seare, Jerry G</au><au>Pinsky, Brett</au><au>Becker, Laura</au><au>Frogel, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association of RSV-related hospitalization and non-compliance with palivizumab among commercially insured infants: a retrospective claims analysis</atitle><jtitle>BMC infectious diseases</jtitle><addtitle>BMC Infect Dis</addtitle><date>2013-07-19</date><risdate>2013</risdate><volume>13</volume><issue>1</issue><spage>334</spage><epage>334</epage><pages>334-334</pages><artnum>334</artnum><issn>1471-2334</issn><eissn>1471-2334</eissn><abstract>Palivizumab has been shown to decrease the incidence of hospitalization due to respiratory syncytial virus (RSV) in infants at risk of severe RSV disease. We examined the association between compliance with palivizumab dosing throughout the RSV season and risk of RSV-related hospitalization in clinical practice.
Subjects who were born and discharged from the hospital before the RSV season and received ≥1 palivizumab dose during their first RSV season were identified from a large US commercial health insurance database between 01/01/03 and 12/31/09. Subjects were deemed compliant if they received ≥5 palivizumab doses without gaps (>35 days) and their first dose was received by November 30. RSV-related hospitalizations were identified using ICD-9-CM diagnosis codes and examined over 2 observation periods: post-index dose and RSV season. A Cox proportional hazard model was used to evaluate the association between non-compliance and RSV-related hospitalization.
Of the 5,003 subjects who received palivizumab, 62% were deemed non-compliant. Non-compliant subjects had significantly higher unadjusted rates of RSV-related hospitalizations compared to compliant subjects during both observation periods (post-index: 6.1 vs. 2.8 per 100 infant seasons, p < 0.001; RSV season: 5.9% vs. 2.3%; p < 0.001). In multivariate analyses, non-compliance was significantly associated with higher risk of RSV-related hospitalization (HR = 2.01; p < 0.001). Of the 225 RSV-related hospitalizations observed during the RSV season, 61 (27%) occurred before the first dose of palivizumab.
Subjects who did not receive monthly dosing of palivizumab throughout the RSV season had significantly higher rates of RSV-related hospitalizations. The RSV-related hospitalizations prior to the first dose of palivizumab suggest some dosing was started too late.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>23870086</pmid><doi>10.1186/1471-2334-13-334</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-2334 |
| ispartof | BMC infectious diseases, 2013-07, Vol.13 (1), p.334-334, Article 334 |
| issn | 1471-2334 1471-2334 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3727980 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central Open Access; Springer Nature OA Free Journals; Springer Nature - Complete Springer Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Antibodies, Monoclonal, Humanized - therapeutic use Antiviral Agents - therapeutic use Biotechnology industry Care and treatment Children & youth Codes Compliance Disease Dosage and administration Drug dosages Drug therapy FDA approval Female For-Profit Insurance Plans - statistics & numerical data Health insurance industry Hospitalization Hospitalization - statistics & numerical data Hospitals Humans Infant Infant, Newborn Infants Insurance Claim Review Male Medication Adherence Methods Multivariate analysis Neuromuscular diseases Palivizumab Patient compliance Pediatrics Pharmacy Pneumonia Respiratory syncytial virus infection Respiratory Syncytial Virus Infections - drug therapy Retrospective Studies Seasons Studies Variables |
| title | Association of RSV-related hospitalization and non-compliance with palivizumab among commercially insured infants: a retrospective claims analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T08%3A57%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20of%20RSV-related%20hospitalization%20and%20non-compliance%20with%20palivizumab%20among%20commercially%20insured%20infants:%20a%20retrospective%20claims%20analysis&rft.jtitle=BMC%20infectious%20diseases&rft.au=Stewart,%20Dan%20L&rft.date=2013-07-19&rft.volume=13&rft.issue=1&rft.spage=334&rft.epage=334&rft.pages=334-334&rft.artnum=334&rft.issn=1471-2334&rft.eissn=1471-2334&rft_id=info:doi/10.1186/1471-2334-13-334&rft_dat=%3Cgale_pubme%3EA534607578%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1417407209&rft_id=info:pmid/23870086&rft_galeid=A534607578&rfr_iscdi=true |